ProCE Banner Activity

ExpressPoints
CDK4/6 Inhibitors in Early-Stage HR+/HER2- Breast Cancer: Individualizing Therapeutic Decisions to Improve Patient Outcomes

Slideset Download

Download this short summary slideset of key takeaway points from a live presentation on the latest data on treatment for patients with HR+/HER2- early breast cancer.

Released: July 09, 2021

Share

Faculty

Javier Cortes

Javier Cortes, MD, PhD

Head, Breast Cancer Program
IOB Institute of Oncology
Madrid and Barcelona, Spain

Stephen R. D. Johnston

Stephen R. D. Johnston, MA, FRCP, PhD

Professor of Breast Cancer Medicine
Breast Unit
Department of Medicine
Royal Marsden Hospital
London, United Kingdom

Sara M. Tolaney

Sara M. Tolaney, MD, MPH

Chief, Division of Breast Oncology
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from

Lilly

Faculty Disclosure

Primary Author

Javier Cortes, MD, PhD

Head, Breast Cancer Program
IOB Institute of Oncology
Madrid and Barcelona, Spain

Stephen R. D. Johnston, MA, FRCP, PhD

Professor of Breast Cancer Medicine
Breast Unit
Department of Medicine
Royal Marsden Hospital
London, United Kingdom

Sara M. Tolaney, MD, MPH

Chief, Division of Breast Oncology
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Sara M. Tolaney, MD, MPH: consultant/advisor/speaker: Aadi Bio, ARC Therapeutics, Artios Pharma, AstraZeneca, Bayer, Blueprint Medicines, Bristol Myers Squibb, CytomX Therapeutics, Daiichi Sankyo, eFFECTOR Therapeutics, Eisai, Eli Lilly, Genentech/Roche, Gilead, Hengrui USA, Incyte Corp, Infinity Therapeutics, Jazz Pharmaceuticals, Menarini/Stemline, Merck, Natera, Novartis, OncXerna, Pfizer, Reveal Genomics, Sanofi, Seattle Genetics, Sumitovant Biopharma, Systimmune, Tango Therapeutics, Umoja Biopharma, Zentalis, Zetagen, Zymeworks; researcher (paid to institution): AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Eisai, Exelixis, Genentech/Roche, Gilead, Lilly, Merck, NanoString Technologies, Novartis, OncoPep, Pfizer, Seattle Genetics.